Synfini Wants to Cut the Cost for Drug Discovery with $53M Raised

For companies looking to find viable therapies, the average timeline from initial discovery to human trials can stretch over a decade, with billions spent and no guarantee of success. Synfini, a Menlo Park-based startup spun out of SRI International, believes it can shorten that timeline with a tightly integrated AI and automation platform that reduces molecular design cycles from months to days. Synfini just announced an $8.9 million expansion round led by JSL Health Capital, bringing its total raised to $53 million. The new funding will help the company scale operations, expand its engineering and scientific teams, and pursue deeper collaborations in therapeutic areas like precision oncology and GPCR-targeted drugs. “We’re building the next generation of drug discovery infrastr